http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2652377-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90b573955a02385ae439930678705347 |
| publicationDate | 2018-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2652377-C2 |
| titleOfInvention | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a novel crystalline form of B (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (compound (I), exhibiting inhibitory activity against PKB (protein kinase B). Compound can be used to treat cancer or to prepare a medicament for treatment PKB activity mediated, in particular, breast cancer, prostate cancer or stomach cancer. Invention also relates to a pharmaceutical composition useful for the treatment of cancer mediated by PKB activity, containing compound (I) in crystalline form B in a therapeutically effective amount, optionally together with microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate. Crystalline form B has an X-ray powder diffraction pattern with at least three characteristic peaks at a 2-theta of about 12.3, 15.0 and 19.2°, in particular, an X-ray powder diffraction pattern with characteristic peaks at 2-theta of about 10.0, 12.3, 15.0, 17.1, 19.2 and 24.4°. n EFFECT: crystalline form B is thermodynamically more stable than other crystalline forms, and is more preferable in terms of the shelf life of the product and minimising the variability in absorption. n 9 cl, 8 dwg, 6 tbl, 3 ex |
| priorityDate | 2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.